KEYNOTE-355: Final results from a randomized, doubleblind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC
Loading...
Identifiers
Publication date
Authors
Advisors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Abstract
Description
UNESCO Subjects
Keywords
Bibliographic reference
Cortés, J., Cescon, D. W., Rugo, H. S., Im, S.-A., Md Yusof, M., Gallardo, C., Lipatov, O., Barrios, C. H., Perez-Garcia, J., Iwata, H., Masuda, N., Torregroza Otero, M., Gokmen, E., Loi, S., Guo, Z., Zhou, X., Karantza, V., Pan, W., & Schmid, P. (2021). KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Annals of Oncology, 32, S1289–S1290. https://doi.org/10.1016/j.annonc.2021.08.2089